On February 3, 2022 Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) reported that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance (Press release, Evotec, FEB 3, 2022, View Source;bayer-discontinues-clinical-development-candidate-eliapixant-bay1817080-evotec-regains-the-rights-to-all-p2x3-assets-6141 [SID1234607740]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following a review of the available data, Bayer concluded that the overall benefit no longer outweighs the risk in the actively pursued indications.

As a consequence of Bayer’s decision, Evotec regains the rights to all P2X3 assets. The Company will evaluate the underlying data as soon as they are made available and will evaluate all options.

This decision has no impact on the overall strategic goals as outlined in Action Plan 2025.